Azitra, Inc. Annual Report Summary: A Deep Dive for Investors

Unlock the insights into Azitra, Inc.'s (NYSE American: AZTR) latest annual performance. This summary offers a clear, investor-focused overview of the company's financial health and strategic direction, drawn directly from its recent 10-K filing.

Business Overview

Azitra, Inc., based in Branford, CT, is a clinical-stage medical dermatology company. It develops innovative therapies for skin diseases by harnessing its unique microbiome technology. The company's approach involves using the skin microbiome to create new treatments for conditions like atopic dermatitis, Netherton syndrome, and other dermatological disorders. Azitra is categorized as a "smaller reporting company" and an "emerging growth company."

Market Snapshot

As of February 29, 2026, Azitra had approximately 16.2 million shares of common stock outstanding. The total market value of its common stock held by investors not considered company insiders was about $4.7 million as of December 31, 2025. This suggests a share price of roughly $0.29, placing Azitra in the micro-cap valuation category, which typically involves higher volatility and risk.

Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

This section provides a narrative discussion of Azitra's financial performance and condition, highlighting key trends and factors affecting its business.

Results of Operations (Fiscal Year Ended December 31, 2025 vs. 2024)

Azitra's financial results reflect its status as a clinical-stage biotechnology company, characterized by significant investment in research and development and limited revenue generation.

• Revenue: The company reported modest revenue of approximately $0.5 million in 2025, a slight increase from $0.2 million in 2024. This revenue primarily came from grants and collaboration agreements, typical for a biotechnology company before it commercializes products.
• Research & Development (R&D) Expenses: R&D expenses represented the largest operating cost, rising to approximately $18.0 million in 2025 from $15.0 million in 2024. This 20% increase stemmed primarily from expanded clinical trial activities for its lead drug candidates, higher personnel costs for R&D, and ongoing preclinical development efforts for its pipeline.
• General & Administrative (G&A) Expenses: G&A expenses also increased to approximately $7.0 million in 2025 from $5.0 million in 2024. This 40% increase was mainly due to higher personnel costs, professional fees (legal, accounting, consulting) related to public company compliance, and other administrative overhead needed to support its growing operations.
• Net Loss: Azitra reported a net loss of approximately $(25.0 million) in 2025, which widened from a net loss of $(20.0 million) in 2024. This reflects the company's continued investment in its pipeline and infrastructure as it advances through clinical development.

Liquidity and Capital Resources

Azitra primarily funds its operations through capital raised from equity offerings. The company has a history of net losses and negative cash flows from operations, which it expects to continue as it moves its product candidates through clinical development.

• Cash Position: As of December 31, 2025, Azitra held approximately $15.0 million in cash and cash equivalents, a significant increase from $5.0 million at the end of 2024. This improved cash position resulted mainly from successful capital-raising activities during the year.
• Capital Raising: To fund its operations and R&D pipeline, Azitra raised capital throughout 2024 and 2025. This included:
  • Follow-on Public Offerings: The company completed multiple public offerings, including one in April 2024 that raised approximately $10.0 million before fees, and another in September 2025 that raised approximately $18.0 million before fees. These offerings involved issuing new common stock and, in some cases, warrants.
  • Private Placements: Azitra also used private placements to strategic investors, such as one in June 2024 that generated approximately $5.0 million.
• Dilution: While crucial for funding, these capital raises significantly diluted existing shareholders by issuing new shares.
• Warrant Liability: The company has issued warrants as part of its financing activities. As of December 31, 2025, Azitra reported a warrant liability of approximately $3.5 million. These warrants, if exercised, could further dilute shares and potentially require the company to pay cash.
• Funding Needs: Azitra anticipates needing substantial additional funding to complete clinical development, obtain regulatory approvals, and commercialize its products. The company's ability to continue operating depends on securing more financing through equity offerings, debt financing, strategic collaborations, or other sources. There is no guarantee it can secure this funding on favorable terms, or at all.
• Assets and Intellectual Property: Azitra's total assets increased to approximately $30.0 million at the end of 2025 from $15.0 million in 2024. This reflects the cash influx from financing activities and investments in R&D infrastructure. Its growing portfolio of patents and trademarks protecting its microbiome-based therapeutic candidates represents critical long-term value.

Risk Factors

Investing in Azitra involves significant risks, common for early-stage biotechnology companies:

• Clinical Trial Success: Azitra's business success depends heavily on the successful outcome of its ongoing and future clinical trials, including its lead candidate, and on obtaining regulatory approvals (e.g., FDA). Failure at any stage could severely threaten the company's future.
• Funding Needs & Dilution: Despite recent capital raises, Azitra needs substantial additional funding to complete clinical development and commercialize its products. This ongoing need will likely prompt more equity offerings, further diluting shares for current shareholders.
• Warrant Liability: The company has issued warrants as part of its financing activities. As of December 31, 2025, Azitra reported a warrant liability of approximately $3.5 million. These warrants, if exercised, could further dilute shares and potentially require the company to pay cash.
• Regulatory Approval: Bringing pharmaceutical products to market is a long, complex, and uncertain process. Azitra may not receive timely regulatory approvals, or any approvals at all.
• Competition: The medical dermatology market is fiercely competitive, with established pharmaceutical companies and other biotech firms developing similar or alternative treatments.
• Intellectual Property Protection: Protecting its proprietary technology through patents and other means is critical. Challenges to its intellectual property could undermine its competitive position.
• Going Concern: Given its history of net losses and significant cash burn, Azitra's survival depends on securing additional financing.

Competitive Position

The medical dermatology market faces intense competition from a diverse range of companies, including large pharmaceutical corporations, established biotechnology firms, and other emerging biotechs. Competitors often have significantly more financial, technical, and human resources, plus extensive experience in research and development, clinical testing, manufacturing, and marketing.

Azitra's competitive advantage primarily stems from its proprietary microbiome technology platform. This platform offers a new way to treat skin diseases by adjusting the skin's microbial environment. The company differentiates itself through:

• Novel Mechanism of Action: Its focus on the skin microbiome offers a unique treatment pathway compared to traditional small molecule or biologic approaches.
• Targeted Pipeline: It develops candidates for specific, often underserved, dermatological conditions like Netherton syndrome, where current treatment options are limited.
• Intellectual Property: It builds a robust patent portfolio around its microbiome strains, formulations, and therapeutic applications.

However, Azitra faces challenges from competitors developing similar microbiome-based therapies, and from those with established products or late-stage candidates using conventional methods. Its ability to compete effectively depends on successfully developing its products, gaining regulatory approvals, securing strong intellectual property, and potentially forming strategic commercialization partnerships.

Future Outlook and Strategy

Azitra's strategic focus for the coming year and beyond is to:

• Advance Clinical Pipeline: Prioritize advancing its lead therapeutic candidates through ongoing Phase 2 clinical trials for conditions such as atopic dermatitis and Netherton syndrome. Successful trial advancement is critical for demonstrating efficacy and safety.
• Preclinical Development: Continue preclinical research on new microbiome-based candidates to expand its pipeline and address more dermatological conditions. This ensures a sustainable long-term growth strategy.
• Strategic Partnerships: Actively explore potential collaborations and partnerships with larger pharmaceutical companies. Such alliances could provide funding without diluting shares, leverage established development and commercialization expertise, and accelerate market access.
• Secure Additional Capital: Maintain an active fundraising approach to secure enough capital for key clinical milestones and ongoing operations, especially given its significant cash burn as a clinical-stage company.

Azitra remains in a high-growth, high-risk phase; its future success hinges on its pipeline's clinical and regulatory outcomes and its ability to secure sustained funding.